Abstract
Essential oils are the volatile fraction of aromatic and medicinal plants after extraction by steam or water distillation. They have been used for their pharmaceutical potential since early times, and even now are still subject to a great deal of attention, as is clear from the increasing number of publications each year on this subject. This review presents both fundamental and recent studies concerned with the role of Nigella species essential oils and their major constituents, thymoquinone and β-elemene, as potential chemotherapeutic and chemopreventive anti-cancer agents. The mechanism of action and the factors which determine the concentrations of these major constituents in the essential oil are also reviewed.
Keywords: Anti-cancer, essential oils, Nigella sativa, Nigella damascene, thymoquinone, β-elemene
Current Clinical Pharmacology
Title: Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene
Volume: 4 Issue: 1
Author(s): Amr E. Edris
Affiliation:
Keywords: Anti-cancer, essential oils, Nigella sativa, Nigella damascene, thymoquinone, β-elemene
Abstract: Essential oils are the volatile fraction of aromatic and medicinal plants after extraction by steam or water distillation. They have been used for their pharmaceutical potential since early times, and even now are still subject to a great deal of attention, as is clear from the increasing number of publications each year on this subject. This review presents both fundamental and recent studies concerned with the role of Nigella species essential oils and their major constituents, thymoquinone and β-elemene, as potential chemotherapeutic and chemopreventive anti-cancer agents. The mechanism of action and the factors which determine the concentrations of these major constituents in the essential oil are also reviewed.
Export Options
About this article
Cite this article as:
Edris E. Amr, Anti-Cancer Properties of Nigella spp. Essential Oils and their Major Constituents, Thymoquinone and β-Elemene, Current Clinical Pharmacology 2009; 4 (1) . https://dx.doi.org/10.2174/157488409787236137
DOI https://dx.doi.org/10.2174/157488409787236137 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Immunotherapeutic Options for Pediatric Malignancies
Current Immunology Reviews (Discontinued) Dysregulation of SIRT-1 Signaling in Multiple Sclerosis and Neuroimmune Disorders: A Systematic Review of SIRTUIN Activators as Potential Immunomodulators and their Influences on other Dysfunctions
Endocrine, Metabolic & Immune Disorders - Drug Targets Ramifications of m6A Modification on ncRNAs in Cancer
Current Genomics The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders
Current Medicinal Chemistry - Central Nervous System Agents Approaches to Targeting Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Functions of Polo-Like Kinases: A Journey From Yeast To Humans
Protein & Peptide Letters Oxidovanadium(IV) Complex Disrupts Mitochondrial Membrane Potential and Induces Apoptosis in Pancreatic Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Molecular Markers of Glial Tumors: Current Targeting Strategies
Current Medicinal Chemistry Statins and the Brain: More than Lipid Lowering Agents?
Current Neuropharmacology Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Targeting the Endocannabinoid System for the Treatment of Cancer – A Practical View
Current Topics in Medicinal Chemistry Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway
Current Topics in Medicinal Chemistry Beneficial Outcomes of Cancer Therapeutic Modalities Based on Targeting Apoptosis
Current Drug Targets Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Topics in Medicinal Chemistry Apoptosis Pathways and Neuroblastoma Therapy
Current Pharmaceutical Design Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Current Cancer Drug Targets